Empliciti (elotuzumab) - Moda Health
Empliciti 300 mg single-dose vial: 00003-2291-xx Empliciti 400 mg single-dose vial: 00003-4522-xx VII. References 1. Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2017. Accessed October 2017. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for elotuzumab. ... Retrieve Here
Empliciti (elotuzumab) - Magellan Provider
Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2017. Accessed October 2017. Empliciti™ (elotuzumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ... Fetch Document
Antineoplastic Agents - BMC HealthNet Plan
Keytruda® (package insert). Whitehouse (NJ): Merck; Jan 2015. + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. ... Doc Viewer
Lyophilized CYTOXAN (cyclophosphamide For Injection, USP ...
Lyophilized CYTOXAN® (cyclophosphamide for injection, USP) CYTOXAN® Tablets (cyclophosphamide tablets, USP) DESCRIPTION Lyophilized CYTOXAN® (cyclophosphamide for injection, USP) is a sterile white lyophilized cake, or partially broken cake, containing 75 mg mannitol per ... Fetch This Document
HIGHLIGHTS OF PRESCRIBING INFORMATION Extended Treatment In ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ... Access This Document
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
Page 3 of 35 FULL PRESCRIBING INFORMATION WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY • Left Ventricular Dysfunction: PERJETA can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. ... Read Full Source
---WARNI NGS A D PRECAUTIONS HIGHLIGHTS OF PRESCRIBING ...
Dosing with THALOMID should usually continue until signs and symptoms of active reaction have subsided, usually a period of at least 2 weeks. Patients may then be tapered off medication in 50 mg decrements every 2 to 4 weeks. ... Content Retrieval
Reference ID: 3853154 - Food And Drug Administration
(elotuzumab) for injection, for intravenous use Initial U.S. Approval: 2015 -----INDICATIONS AND USAGE-----EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of ... View This Document
Isatuximab - Wikipedia
Isatuximab is a monoclonal antibody (mAb) designed for the treatment of cancer. It was developed by ImmunoGen and Sanofi-Aventis with the development name SAR-650984 . It was given orphan drug status for multiple myeloma by the FDA in December 2016. ... Read Article
Veltuzumab - Wikipedia
Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.. This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106. ... Read Article
Reference ID: 3851135
3 - Patient experiences Grade 3 skin induration/fibrosis [see Warnings and Precautions (5.4) and Adverse Reactions (6.1)] or - Grade 4 dermatologic toxicity ... Get Doc
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI. EMPLICITI® (elotuzumab) for injection, for intravenous use Initial U.S. Approval: 2015----- RECENT MAJOR CHANGES----- ... Retrieve Here
Monoclonal Antibodies In Multiple Myeloma
Daratumumab Elotuzumab ~3.5 hour infusion Daratumumab [package insert]: Horsham, PA: Janssen Biotech; 2018 ~1 hour infusion Elotuzumab [package insert]: Princeton, NJ: Bristol-Myers Squibb; 2017 Future of Monoclonal Antibodies in MM New combinations and first line approvals New formulations SQ daratumumab New monoclonal antibodies ... Access Document
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CYRAMZAsafely and effectively. See full prescribing information ... Access Document
New Drug Updates In Hematology/Oncology
Elotuzumab Dosing CYCLE 1,2 3+ (UNTIL PROGRESSION) DAY OF CYCLE 1 8 15 22 1 8 15 22 ELOTUZUMAB 10 mg/kg 10 mg/kg 10 mg/kg LENALIDOMIDE 25 mg PO days 1-21 DEXAMETHASONE PO 28 mg 28 mg 40 mg 28 mg 40 mg DEXAMETHASONE IV 8 mg 8 mg 8 mg Bristol-Myers Squibb. Empliciti (elotuzumab) package insert. Princeton, NJ; 2015. ... Read Full Source
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Each vial contains 300 mg elotuzumab*. Empliciti 400 mg powder for concentrate for solution for infusion Each vial contains 400 mg elotuzumab. After reconstitution, each mL of concentrate contains 25 mg elotuzumab. * Elotuzumab is produced in NS0 cells by recombinant DNA technology. ... Return Document
HIGHLIGHTS OF PRESCRIBING INFORMATION Posterior Reversible ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE XTANDI® is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC). 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information The recommended dose of XTANDI is 160 mg (four 40 mg capsules) administered orally once daily. ... Access Full Source
EMPLICITI (elotuzumab) - Caremark
EMPLICITI (elotuzumab) Empliciti FEP Clinical Rationale RATIONALE FOR INCLUSION IN PA PROGRAM Background Empliciti is a monoclonal antibody that specifically targets the SLAMF7 protein. Multiple myeloma is a cancer that forms in a type of white blood cell called plasma cells. SLAMF7 protein is expressed on both myeloma and natural killer cells. ... Retrieve Doc
Intron A PI - Merck.com
This is a multidose vial which contains a total of 32.0 million IU of interferon alfa-2b, recombinant per 3.2 mL in order to provide the delivery of five 0.5-mL doses, each containing 5 million IU of INTRON A (for a label strength of 25 million IU). ... Return Doc
Empliciti (elotuzumab) - Magellan Provider
Empliciti 300 mg single-dose vial: 00003-2291-xx Empliciti 400 mg single-dose vial: 00003-4522-xx VII. References 1. Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2017. Accessed October 2017. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for elotuzumab. ... Fetch Full Source
